APRE News and Press, Aprea Therapeutics Inc. From 04/13/21

Aprea Therapeutics Inc. (NASDAQ:APRE) traded at a new 52-week low today of $4.31. So far today approximately 1.9 million shares have been exchanged, as compared to an average 30-day volume of 1.1 million shares. Over the past year, Aprea Therapeutics Inc. has traded in a range of $4.31 t...

Aprea Therapeutics shares jump ([[APRE]] +15.3%) announces that the U.S. FDA has granted Orphan Drug designation to eprenetapopt for treatment of acute myeloid leukemia ((AML)).Orphan Drug status is granted by the FDA Office of Orphan Products Development to advance the evaluation and de...

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administr...

Aprea Therapeutics (APRE): Q4 GAAP EPS of -$0.73 misses by $0.10.Cash and cash equivalents of $89M.Press Release For further details see: Aprea Therapeutics EPS misses by $0.10

BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three m...

Today, we take our first look at Aprea Therapeutics, a small oncology concern based out of Boston. Like so many small biotech concerns, the stock soon has found itself in Busted IPO territory just over a year after it debuted on the markets. A recent trial failure has crushed the ...

The following slide deck was published by Aprea Therapeutics, Inc. in conjunction with this event. For further details see: Aprea Therapeutics (APRE) Presents at J.P. Morgan Healthcare Conference 2021 - Slideshow

Aprea Therapeutics (APRE) updates in company presentation disclosure that the Company had $89M of cash and cash equivalents as of December 31, 2020.Also, the company reports no outstanding debt.Anticipates cash burn of $30M-35M in 2021.The existing cash should fund operations into 2023.Compan...

BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. A drifting New Year's Eve stock market kicked into bullish mode in the last two hours of trading Thursday, helping the S&P 500 and the Do...